Genmab — December 2022
-
Genmab og partneren Janssen må se et nyt udviklingssamarbejde forme sig mellem medicinalkæmpen Pfizer og biotekselskabet Oric Pharmaceuticals inden for knoglemarvskræft. https://www.proinvestor.com/investornyt/919033/amerikansk-biotekaktie-tager-pa-raketfart-oven-pa-pfizer-samarbejde
-
Der er ikke meget likviditet i handlen med aktier for tiden. Vi kan efterhånden konstatere, at julerally udebliver i år, og det samme gør nytårsraketterne på aktiemarkedet. Mere om det i denne uges kommentar fra Helge Larsen. Derudover kommer han ind på Danske Bank, Tesla, Genmab og Zealand Pharma
https://www.proinvestor.com/boards/108892 -
-
@Sukkeralf, er aftalen med Bolt ikke noget lignende ADC https://ir.genmab.com/news-releases/news-release-details/genmab-and-bolt-biotherapeutics-announce-oncology-research-and/
-
Immune-stimulating Antibody Conjugate (ISAC)
The technical requirements of immune-stimulating antibody conjugate (ISAC) are very similar to ADC, except that the ISAC load is an innate immune agonist or modulator that enables the ability to convert cold tumors into immune hot tumors. Also, similar in function to tumor microenvironment activated drug conjugates (TMAC) in part, both achieve activation of immune killing and therapeutic sensitization by modulating immune stimulation and microenvironm -
-
Godmorgen
-
-
Tak Sukkeralf, så Genmab er med på ADC toget
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind